A systematic review identified five studies that included 307 vedolizumab-treated patients with IBD, 490 anti-TNFα-treated patients with IBD, and 535 patients with IBD who were not exposed to pre-operative biologic therapy, in total. This evidence concerns the gene TNF and inflammatory bowel disease.